STAT3 and neoplasm: In line with the fact that Ruxo is a well-established JAK1/2 inhibitor, we observed the expected suppression of p-JAK2 and p-STAT3 in tumor (CD45−) cells by Ruxo (Supplementary Fig. 6d).